利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

2 条记录 (耗时 0.03 秒)

    Susceptibility to HSP90-Inhibitors
    2.
    发明申请
    Susceptibility to HSP90-Inhibitors 审中-公开
    对HSP90抑制剂的敏感性

    公开(公告)号：US20110319415A1

    公开(公告)日：2011-12-29

    申请号：US13059557

    申请日：2009-08-17

    申请人： Roman Thomas ,  Kathrin Maring ,  Thomas Zander ,  Peter Frommolt ,  Kwok-kin Wong

    发明人： Roman Thomas ,  Kathrin Maring ,  Thomas Zander ,  Peter Frommolt ,  Kwok-kin Wong

    IPC分类号： A61K31/395 ,  C12Q1/68 ,  G01N33/567 ,  A61K31/5377 ,  A61P35/00 ,  A61P35/02 ,  C40B30/04 ,  C12Q1/02

    CPC分类号： G01N33/574 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/156 ,  G01N2800/52

    摘要： The present invention relates to a method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to an HSP90 inhibitor. Also a method for determining the responsiveness of a mammalian tumor cell or cancer cell to treatment with an HSP90 inhibitor is described herein. In particular, the present invention provides for an in vitro method for the identification of a responder for or a patient sensitive to an HSP90 inhibitor and uses of an oligo- or polynucleotide capable of detecting (an) activating mutation(s) in the KRAS gene are provided. The present invention also relates to a method of monitoring the efficacy of a treatment of a cancer characterized by the presence of at least one activating mutation in the KRAS gene, and. optionally, in the EGFR gene and/or the BRAF gene. In addition, a method of predicting the efficacy of a cancer treatment is described, in particular in a cancer that is characterized by the presence of at least one activating mutation in the KRAS gene. and. optionally, in the EGFR gene and/or the BRAF gene. Also the use of a (transgenic) non-human animal or a (transgenic) cell having at least one activating mutation in the KRAS gene, and, optionally, in the EGFR gene and/or the BRAF gene for screening and/or validation of a medicament for the treatment of said cancer is described and a kit useful for carrying out the methods described herein is provided.

    摘要翻译： 本发明涉及一种选择（a）对HSP90抑制剂具有敏感性的细胞，（a）组织或（a）细胞培养物的方法。 本文还描述了确定哺乳动物肿瘤细胞或癌细胞对用HSP90抑制剂进行治疗的反应性的方法。 特别地，本发明提供了用于鉴定对HSP90抑制剂敏感的或对其敏感的患者的体外方法，以及能够检测（或）激活KRAS基因突变的寡核苷酸或多核苷酸的用途 被提供。 本发明还涉及一种监测癌症治疗功效的方法，其特征在于在KRAS基因中存在至少一种激活突变。 任选地，在EGFR基因和/或BRAF基因中。 此外，描述了预测癌症治疗功效的方法，特别是在KRAS基因中存在至少一种激活突变的癌症中。 和。 任选地，在EGFR基因和/或BRAF基因中。 另外，在KRAS基因和/或任选地在EGFR基因和/或BRAF基因中具有至少一个激活突变的（转基因）非人动物或（转基因）细胞也用于筛选和/或验证 描述了用于治疗所述癌症的药物，并提供了可用于实施本文所述方法的试剂盒。